Skip to main content
SpringerLink
Log in

Pharmacokinetic Properties of Phosphorothioates in Animals — Absorption, Distribution, Metabolism and Elimination

  • Chapter
Antisense Research and Application

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 131))

Abstract

Antisense oligonucleotides can hybridise with target mRNA and cause protein-specific translation arrest (Zamecnik and Stevenson 1978; Helene and Toulme 1990). This “antisense concept” is a simple, generic and rational approach to drug discovery which has stimulated considerable interest in the potential of oligonucleotides as therapeutic agents (Crooke 1995). Indeed, there are now many examples where antisense oligonucleotides have demonstrated efficacy against disease-relevant targets, notably for tumour (Higgins et al. 1993; Monia et al. 1996; Dean et al. 1996) and viral (Agrawal 1992; Wagner and Flanagan 1997) indications. The rapid emergence of this class of compounds has placed new demands on the preclinical profiling of therapeutic candidates, particularly with respect to their in vivo behaviour.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 429.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 549.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agrawal S (1992) Antisense oligonucleotides as antiviral agents. Trends Biotechnol Sci 10:152–157

    Article  CAS  Google Scholar 

  • Agrawal S, Temsamani J, Tang JY (1991) Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595–7599

    Article  PubMed  CAS  Google Scholar 

  • Agrawal S, Temsamani J, Galbraith W, Tang J (1995a) Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28:7–16

    Article  CAS  Google Scholar 

  • Agrawal S, Zhang X, Lu Z, Hui Z, Tamburin JM, Yan J, Cai H, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Zhang R (1995b) Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 50:571–576

    Article  CAS  Google Scholar 

  • Artursson P, Karlsson J (1991) Correlation between oral absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cell culture. Biochem Biophys Res Commun 175:880–885

    Article  PubMed  CAS  Google Scholar 

  • Beck GF, Irwin WJ, Nicklin PL, Akhtar S (1996) Interactions of phosphodiester and phosphorothioate oligonucleotides with intestinal epithelial Caco-2 cells. Pharmacol Res 13:1028–1037

    Article  CAS  Google Scholar 

  • Carome MA, Kang YH, Bohen EM, Nicholson DE, Carr FE, Kiandoli LC, Brummel SE, Yuan CM (1997) Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo. Nephron 75:82–87

    Article  PubMed  CAS  Google Scholar 

  • Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins LL, Owens SR, Markham PM, Shea JP, Crooke ST (1993) Disposition of the ’4C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267:1181–1190

    PubMed  CAS  Google Scholar 

  • Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins L, Owens SR, Markham PM, Shea JP, Crooke ST (1994) Disposition of the“C-labeled phosphorothioate oligonucleotide ISIS 2105 after intradermal administration to rats. J Pharmacol Exp Ther 269:89–94

    PubMed  CAS  Google Scholar 

  • Crooke ST (1995) Therapeutic applications of oligonucleotides. Landes, Austin, Texas

    Google Scholar 

  • Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Kornburst D, Manoharan M, Sasmor H, Schleich T, Tivel KL, Griffey R (1996) Pharmacokinetic properties of several oligonucleotide analogs in mice. J Pharmacol Exp Ther 277:923–937

    PubMed  CAS  Google Scholar 

  • Dean NM, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin PL, Miester L, Ziel R, Geiger T, Müller M, Fabbro D (1996) Inhibition of human tumor cell lines in nude mice by an antisense inhibitor of PKC-a expression. Cancer Res 56:3499–3507

    PubMed  CAS  Google Scholar 

  • De Serres M, McNulty MJ, Christensen L, Zon G, Findlay JWA (1996) Development of a novel scintillation proximity competitive hybridisation assay for the determination of phosphorothioate antisense oligonucleotide plasma concentrations in a toxicokinetic study. Anal Biochem 233:228–233

    Article  PubMed  Google Scholar 

  • Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S (1994) Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4:201–206

    PubMed  CAS  Google Scholar 

  • Gaus HJ, Owens SR, Winniman M, Cooper S, Cummins LL (1997) On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem 69(3):313–319

    Article  PubMed  CAS  Google Scholar 

  • Goodarzi G, Watabe M, Watabe K (1992) Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice. Biopharm Drug Dispos 13:221–227

    Article  PubMed  CAS  Google Scholar 

  • Graham MJ, Freier SM, Crooke RM, Ecker DJ, Maslova RN, Lesnik EA (1993) Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res 21:3737–3743

    Article  PubMed  CAS  Google Scholar 

  • Helene C, Toulme JJ (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049:99–125

    Article  PubMed  CAS  Google Scholar 

  • Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R (1993) Antisense inhibition of the p65 subunit of NF- B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 90:9901–9905

    Article  PubMed  CAS  Google Scholar 

  • Inagaki M, Togawa K, Carr BL, Ghosh K, Cohen JS (1992) Antisense oligonucleotides: inhibition of liver cell proliferation and in vivo disposition. Transplant Proc 24:2971–2972

    PubMed  CAS  Google Scholar 

  • Iversen P (1991) In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anti Cancer Drug Des 6:531–538

    CAS  Google Scholar 

  • Iversen P, Mata J, Tracewell WG, Zon G (1994) Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusions. Antisense Res Dev 4:43–52

    PubMed  CAS  Google Scholar 

  • Kisner D (1996) Development of phosphorothioate oligonucleotides. Proceedings of the XII international roundtable: nucleosides, nucleotides and their biological applications, La Jolla, CA

    Google Scholar 

  • Leeds JM, Graham MJ, Truong L, Cummins LL (1996) Quantification of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235:36–43

    Article  PubMed  CAS  Google Scholar 

  • Mackay M, Phillips JA, Steward A, Hastewell JG (1994) Pulmonary absorption of therapeutic peptides and proteins. In: Byron PR, Dalby RN, Farr SJ (eds) Respiratory drug delivery IV. Buffalo Grove, IL, Interpharm Press, pp 31–37

    Google Scholar 

  • Monia BP, Johnston JF, Geiger T, Müller M, Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nature Med 2:668–675

    Article  PubMed  CAS  Google Scholar 

  • Nicklin PL, Irwin WJ, Hassan IF, Williamson I, Mackay M (1992) Permeable support type influences the transport of compounds across Caco-2 cells. Int J Pharmacol 83:197–209

    Article  CAS  Google Scholar 

  • Nicklin PL, Irwin WJ, Hassan IF, Mackay M, Dixon HBF (1995) The transport of acidic amino acids and their analogues across monolayers of human intestinal absorptive (Caco-2) cells in vitro. Biochim Biophys Acta 1269:176–186

    Article  PubMed  Google Scholar 

  • Oberbauer R, Schreiner GF, Meyer TW (1995) Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int 48:1226–1232

    Article  PubMed  CAS  Google Scholar 

  • Oberbauer R, Murer H, Schreiner GF, Meyer TW (1996) Antisense and the kidney. Kidney Blood Press Res 19:221–224

    Article  PubMed  CAS  Google Scholar 

  • Phillips JA, Nicklin PL (1996) The pulmonary route: potential for the non-parenteral delivery of oligonucleotides? In: Proceedings of the international congress: therapeutic oligonucleotides, Rome, Italy, 10–12 June 1996

    Google Scholar 

  • Phillips JA, Craig SJ, Nicklin PL (1996) Dose-dependent disposition of a 20-mer phosphorothioate oligonucleotide (CGP 69846A) after intravenous administration. Proceedings of the international congress: therapeutic oligonucleotides, Rome, Italy

    Google Scholar 

  • Phillips JA, Craig SJ, Bayley D, Christian RA, Geary R, Nicklin PL (1997) Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 54:657–668, 1997

    Google Scholar 

  • Pinto M, Robine-Leon S, Appay MD, Kedinger M, Triadou N, Dussalux E, Lacroix B, Assman S, Haffen P, Fogh J, Zweibaum A (1983) Enterocyte-like differentiation and polarisation of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47:323–330

    Google Scholar 

  • Rifai A, Brysch W, Fadden K, Clark J, Schlingensiepen K-H (1996) Clearance kinetics, biodistribution and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am J Pathol 149:717–725

    PubMed  CAS  Google Scholar 

  • Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL (1994) Biodistribution and metabolism of internally 3H-labeled oligonucleotides. 1. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45:932–943

    PubMed  CAS  Google Scholar 

  • Sawai K, Mahato RI, Oka Y, Takakura Y, Hashida M (1996) Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake. J Pharmacol Exp Ther 279:284–290

    PubMed  CAS  Google Scholar 

  • Schechter PJ, Martin RR, Grindel JM (1996) Clinical results of drug candidates. Proceedings of the XII international roundtable: nucleosides, nucleotides and their biological applications, La Jolla, CA

    Google Scholar 

  • Shaw DR, Rustagi PK, Kandimalla ER, Manning AN, Jiang Z, Agrawal S (1997) Effect of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol 53:1123–1132

    Article  PubMed  CAS  Google Scholar 

  • Spitzer S, Eckstein F (1988) Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides. Nucleic Acids Res 16:11691–11704

    Article  PubMed  CAS  Google Scholar 

  • Stein CA (1996) Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends Biotechnol 14:147–149

    Article  PubMed  CAS  Google Scholar 

  • Tang JY, Temsamani J, Agrawal S (1993) Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity. Nucleic Acids Res 21:2729–2735

    Article  PubMed  CAS  Google Scholar 

  • Temsamani J, Tang JY, Padmapriya A, Kubert M, Agrawal S (1993) Pharmacokinetics, biodistribution and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res Dev 3:277–284

    PubMed  CAS  Google Scholar 

  • Wagner RW, Flanagan M (1997) Antisense technology and prospects for therapy of viral infections and cancer. Mol Med Today 3:31–38

    Article  PubMed  CAS  Google Scholar 

  • Williamson I, Phillips JA, Nicklin PL (1995) Pharmacokinetics, organ distribution and cellular uptake of phosphorothioate oligonucleotides in vivo. Proceedings of therapeutic oligonucleotides from cell to man, Selliac, France

    Google Scholar 

  • Zamecnik PC, Stevenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75:280–284

    Article  PubMed  CAS  Google Scholar 

  • Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S (1995a) Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM-91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49:929–939

    Article  CAS  Google Scholar 

  • Zhang R, Lu Z, Zhang X, Zhao H, Diasio RB, Liu T, Jiang Z, Agrawal S (1995b) In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin Chem 41:836–843

    CAS  Google Scholar 

Download references

Authors
  1. P. L. Nicklin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. J. Craig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. A. Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. ISIS Pharmaceuticals, Inc., Carlsbad Research Center, 2292 Faraday Avenue, Carlsbad, CA, 92008, USA

    Stanley T. Crooke M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Nicklin, P.L., Craig, S.J., Phillips, J.A. (1998). Pharmacokinetic Properties of Phosphorothioates in Animals — Absorption, Distribution, Metabolism and Elimination. In: Crooke, S.T. (eds) Antisense Research and Application. Handbook of Experimental Pharmacology, vol 131. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58785-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-58785-6_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63730-8

  • Online ISBN: 978-3-642-58785-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation